GlassScriptPhysician profile
Ronald Joseph Carr
NPI 1700803269
$29,599.72
in general payments reported to CMS, 2019-2025
31 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,407 · 2020: $1,881 · 2021: $6,338 · 2022: $1,911 · 2023: $12K · 2024: $2,803 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $5,064 · Travel and Lodging: $639 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,323.87 |
| Food and Beverage | $5,064.38 |
| Travel and Lodging | $638.96 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $12,515.38 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Kala Pharmaceuticals, INC. | $6,923.04 | 2019-2022 | |
| Alcon Vision LLC | $3,026.16 | 2019-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Biotissue Holdings INC. | $1,260.26 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $1,073.84 | 2020-2025 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $844.59 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Glaukos Corporation | $446.65 | 2019-2025 | Idosetr, Istent Infinite |
| Allergan, INC. | $439.22 | 2019-2022 | |
| Abbvie INC. | $353.94 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $303.11 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $276.51 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $270.34 | 2024-2025 | Vevye |
| Dompe US, INC. | $235.24 | 2019-2025 | Oxervate |
| Notal Vision, INC. | $207.05 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $203.37 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $200.27 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $198.33 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $119.73 | 2021-2022 | |
| Thea Pharma INC. | $118.23 | 2022-2024 | Iyuzeh |
| Coopervision INC. | $108.12 | 2019 | |
| Sight Sciences, INC. | $101.08 | 2019-2020 | |
| Oyster Point Pharma, INC. | $90.58 | 2022-2023 | Tyrvaya |
| Lensar, INC. | $60.56 | 2019 | |
| Abb Con-Cise Optical Group LLC | $54.22 | 2023 | Contact Lens, Spectacle Lenses |
| Shire North American Group INC | $39.56 | 2019 | |
| Optos, INC. | $33.27 | 2020-2022 | |
| Tearlab Corp | $25.41 | 2024 | Scoutpro Osmolarity System |
| Staar Surgical Company | $25.33 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $23.38 | 2019 | |
| Carl Zeiss Meditec, INC. | $20.68 | 2019 | |
| New World Medical,INC. | $2.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.